Effect of Tocilizumab in Mortality among Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center.

Bernardo A Martínez-Guerra, Nereyda A de-León-Cividanes, Karla M Tamez-Torres, Carla M Román-Montes, Sandra Rajme-López, Edgar Ortiz-Brizuela, Carlos A Aguilar-Salinas, Juan Sierra-Madero, José Sifuentes-Osornio, Alfredo Ponce-de-León, María F González-Lara
{"title":"Effect of Tocilizumab in Mortality among Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center.","authors":"Bernardo A Martínez-Guerra,&nbsp;Nereyda A de-León-Cividanes,&nbsp;Karla M Tamez-Torres,&nbsp;Carla M Román-Montes,&nbsp;Sandra Rajme-López,&nbsp;Edgar Ortiz-Brizuela,&nbsp;Carlos A Aguilar-Salinas,&nbsp;Juan Sierra-Madero,&nbsp;José Sifuentes-Osornio,&nbsp;Alfredo Ponce-de-León,&nbsp;María F González-Lara","doi":"10.24875/RIC.21000404","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Trials evaluating safety and efficacy of tocilizumab in coronavirus disease 19 (COVID-19) show contradictory results.</p><p><strong>Objective: </strong>The objective of the study was to evaluate the effect of tocilizumab in hospital mortality among patients with severe COVID-19 in a third-level medical center.</p><p><strong>Methods: </strong>This prospective cohort study included patients with severe and critical COVID-19. Primary outcome was death during hospitalization. Secondary outcomes included invasive mechanical ventilation (IMV), days on IMV, ventilator-free days (VFDs), length of hospital stay (LOS), and development of hospitalacquired infections (HAIs). Bivariate, multivariate, and propensity score matching analysis were performed.</p><p><strong>Results: </strong>During the study period, 99/794 (12%) patients received tocilizumab. Male patients, health care workers, and patients with increased inflammatory markers received tocilizumab more frequently. No difference in hospital mortality was observed between groups (34% vs. 34%, p = 0.98). Tocilizumab was not independently associated with mortality. No significant treatment effects were observed in propensity score analysis. IMV was more frequent (46% vs. 11%, p < 0.01) and LOS was longer (12 vs. 7 days, p < 0.01) in the tocilizumab group, reflecting increased severity. Although HAIs were more frequent in the tocilizumab group (22% vs. 10%, p < 0.01), no difference was seen after adjusting for IMV (38% vs. 40%, p = 0.86).</p><p><strong>Conclusions: </strong>In our study, tocilizumab was not associated with decreased hospital mortality among patients with severe COVID-19.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"74 1","pages":"40-50"},"PeriodicalIF":1.4000,"publicationDate":"2022-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista De Investigacion Clinica-Clinical and Translational Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.24875/RIC.21000404","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

Abstract

Background: Trials evaluating safety and efficacy of tocilizumab in coronavirus disease 19 (COVID-19) show contradictory results.

Objective: The objective of the study was to evaluate the effect of tocilizumab in hospital mortality among patients with severe COVID-19 in a third-level medical center.

Methods: This prospective cohort study included patients with severe and critical COVID-19. Primary outcome was death during hospitalization. Secondary outcomes included invasive mechanical ventilation (IMV), days on IMV, ventilator-free days (VFDs), length of hospital stay (LOS), and development of hospitalacquired infections (HAIs). Bivariate, multivariate, and propensity score matching analysis were performed.

Results: During the study period, 99/794 (12%) patients received tocilizumab. Male patients, health care workers, and patients with increased inflammatory markers received tocilizumab more frequently. No difference in hospital mortality was observed between groups (34% vs. 34%, p = 0.98). Tocilizumab was not independently associated with mortality. No significant treatment effects were observed in propensity score analysis. IMV was more frequent (46% vs. 11%, p < 0.01) and LOS was longer (12 vs. 7 days, p < 0.01) in the tocilizumab group, reflecting increased severity. Although HAIs were more frequent in the tocilizumab group (22% vs. 10%, p < 0.01), no difference was seen after adjusting for IMV (38% vs. 40%, p = 0.86).

Conclusions: In our study, tocilizumab was not associated with decreased hospital mortality among patients with severe COVID-19.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
托珠单抗对重症和危重型Covid-19患者死亡率的影响:在三级医疗中心的经验
背景:评估托珠单抗治疗冠状病毒病19 (COVID-19)的安全性和有效性的试验结果相互矛盾。目的:本研究的目的是评估托珠单抗对三级医疗中心重症COVID-19患者住院死亡率的影响。方法:本前瞻性队列研究纳入重症和危重型COVID-19患者。主要结局为住院期间死亡。次要结局包括有创机械通气(IMV)、使用IMV天数、无呼吸机天数(vfd)、住院时间(LOS)和院内获得性感染(HAIs)的发生。进行了双变量、多变量和倾向评分匹配分析。结果:在研究期间,99/794(12%)患者接受了tocilizumab治疗。男性患者、卫生保健工作者和炎症标志物升高的患者更频繁地接受托珠单抗治疗。两组住院死亡率无差异(34% vs. 34%, p = 0.98)。托珠单抗与死亡率无独立相关性。倾向评分分析未观察到显著的治疗效果。托珠单抗组IMV更频繁(46% vs. 11%, p < 0.01), LOS更长(12 vs. 7天,p < 0.01),反映了严重程度的增加。虽然HAIs在tocilizumab组更常见(22% vs. 10%, p < 0.01),但在调整IMV后没有发现差异(38% vs. 40%, p = 0.86)。结论:在我们的研究中,托珠单抗与重症COVID-19患者住院死亡率的降低无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.00
自引率
0.00%
发文量
60
审稿时长
>12 weeks
期刊介绍: The Revista de Investigación Clínica – Clinical and Translational Investigation (RIC-C&TI), publishes original clinical and biomedical research of interest to physicians in internal medicine, surgery, and any of their specialties. The Revista de Investigación Clínica – Clinical and Translational Investigation is the official journal of the National Institutes of Health of Mexico, which comprises a group of Institutes and High Specialty Hospitals belonging to the Ministery of Health. The journal is published both on-line and in printed version, appears bimonthly and publishes peer-reviewed original research articles as well as brief and in-depth reviews. All articles published are open access and can be immediately and permanently free for everyone to read and download. The journal accepts clinical and molecular research articles, short reports and reviews. Types of manuscripts: – Brief Communications – Research Letters – Original Articles – Brief Reviews – In-depth Reviews – Perspectives – Letters to the Editor
期刊最新文献
Proposal of a functional prognostic scale in mexican patients with Guillain-Barré syndrome. LINC01614 activated by SP1 promoted malignant behavior of triple-negative breast cancer cells via the WNT/b-Catenin signaling pathway. Expanding Diagnostic Workup for hypertensive Intracerebral hemorrhage: a retrospective LATAM cerebrovascular registry comparison. Genotypes distribution of the SNP RS1477196 of FTO gen associated with primary knee osteoarthritis in females: an analysis using the 100Genomes database. Validation of the HAS-BLED scale for the assessment of bleeding risk in patients on anticoagulation therapy with a diagnosis of venous thromboembolic disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1